IL17A and neoplasm: In one study, deletion of the genes encoding either IL-17A or its receptor (IL-17AR) was found to confer protection against tumor promotion and progression, while combining administration of an anti-IL-17A MAb together with chemotherapy was found to enhance therapeutic efficacy (128).